<DOC>
	<DOCNO>NCT00027638</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth neuroendocrine tumor stop blood flow tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Metastatic Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy thalidomide patient metastatic low-grade neuroendocrine tumor . OUTLINE : Patients receive oral thalidomide daily week 1-8 . Courses repeat every 8 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade neuroendocrine tumor Carcinoid tumor Islet cell tumor Metastatic disease Progression disease within past 4 week radiological evidence At least 1 bidimensionally measurable lesion CT scan MRI Bone metastasis consider measurable site disease No active brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 4 week , , 4 week study No grade 2 great neuropathy No clinical circumstance would preclude study No prior malignancy except : Nonmelanoma skin cancer Other cancer curatively treat , evidence recurrence within past 5 year , low risk recurrence PRIOR CONCURRENT THERAPY : Biologic therapy : No prior thalidomide No concurrent interferon Chemotherapy : No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior major surgery Other : No 1 prior systemic therapy regimen At least 4 week since prior systemic therapy regimen No concurrent therapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
</DOC>